Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care ...
Myotonic dystrophy type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely ...
News Medical on MSN1d
Testing a novel approach to restore normal heart function in Myotonic Dystrophy Type 1Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs including skeletal muscle, heart, brain and the ...
nottinghamworld.com on MSN1d
Gabby Logan presents Nottingham Research Scientist with charity awardOn Monday 17 March, the Muscular Dystrophy UK President’s Awards took place, in association with Airnow Technology and hosted ...
Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
About the rSM Program to Treat Myotonic Dystrophy Type 1 (DM1) Myotonic dystrophy type 1 (DM1) is a form of muscular dystrophy and a genetic neuromuscular disease affecting at least 1 in 8,000 ...
BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback